TY - JOUR
T1 - Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy
AU - Ferreri, Christopher J.
AU - Hildebrandt, Michelle A.T.
AU - Hashmi, Hamza
AU - Shune, Leyla O.
AU - McGuirk, Joseph P.
AU - Sborov, Douglas W.
AU - Wagner, Charlotte B.
AU - Kocoglu, M. Hakan
AU - Rapoport, Aaron
AU - Atrash, Shebli
AU - Voorhees, Peter M.
AU - Khouri, Jack
AU - Dima, Danai
AU - Afrough, Aimaz
AU - Kaur, Gurbakhash
AU - Anderson, Larry D.
AU - Simmons, Gary
AU - Davis, James A.
AU - Kalariya, Nilesh
AU - Peres, Lauren C.
AU - Lin, Yi
AU - Janakiram, Murali
AU - Nadeem, Omar
AU - Alsina, Melissa
AU - Locke, Frederick L.
AU - Sidana, Surbhi
AU - Hansen, Doris K.
AU - Patel, Krina K.
AU - Castaneda Puglianini, Omar Alexis
N1 - Publisher Copyright:
© 2023, Springer Nature Limited.
PY - 2023/12
Y1 - 2023/12
N2 - Most patients with multiple myeloma experience disease relapse after treatment with a B-cell maturation antigen-targeted therapy (BCMA-TT), and data describing outcomes for patients treated with sequential BCMA-TT are limited. We analyzed clinical outcomes for patients infused with standard-of-care idecabtagene vicleucel, an anti-BCMA chimeric antigen receptor (CAR) T-cell therapy, at 11 US medical centers. A total of 50 patients with prior BCMA-TT exposure (38 antibody-drug conjugate, 7 bispecific, 5 CAR T) and 153 patients with no prior BCMA-TT were infused with ide-cel, with a median follow-up duration of 4.5 and 6.0 months, respectively. Safety outcomes between cohorts were comparable. The prior BCMA-TT cohort had a lower overall response rate (74% versus 88%; p = 0.021), median duration of response (7.4 versus 9.6 months; p = 0.03), and median progression-free survival (3.2 months versus 9.0 months; p = 0.0002) compared to the cohort without prior BCMA-TT. All five patients who received a prior anti-BCMA CAR T responded to ide-cel, and survival outcomes were best for this subgroup. In conclusion, treatment with ide-cel yielded meaningful clinical responses in real-world patients exposed to a prior BCMA-TT, though response rates and durability were suboptimal compared to those not treated with a prior BCMA-TT.
AB - Most patients with multiple myeloma experience disease relapse after treatment with a B-cell maturation antigen-targeted therapy (BCMA-TT), and data describing outcomes for patients treated with sequential BCMA-TT are limited. We analyzed clinical outcomes for patients infused with standard-of-care idecabtagene vicleucel, an anti-BCMA chimeric antigen receptor (CAR) T-cell therapy, at 11 US medical centers. A total of 50 patients with prior BCMA-TT exposure (38 antibody-drug conjugate, 7 bispecific, 5 CAR T) and 153 patients with no prior BCMA-TT were infused with ide-cel, with a median follow-up duration of 4.5 and 6.0 months, respectively. Safety outcomes between cohorts were comparable. The prior BCMA-TT cohort had a lower overall response rate (74% versus 88%; p = 0.021), median duration of response (7.4 versus 9.6 months; p = 0.03), and median progression-free survival (3.2 months versus 9.0 months; p = 0.0002) compared to the cohort without prior BCMA-TT. All five patients who received a prior anti-BCMA CAR T responded to ide-cel, and survival outcomes were best for this subgroup. In conclusion, treatment with ide-cel yielded meaningful clinical responses in real-world patients exposed to a prior BCMA-TT, though response rates and durability were suboptimal compared to those not treated with a prior BCMA-TT.
UR - http://www.scopus.com/inward/record.url?scp=85167528857&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85167528857&partnerID=8YFLogxK
U2 - 10.1038/s41408-023-00886-8
DO - 10.1038/s41408-023-00886-8
M3 - Article
C2 - 37558706
AN - SCOPUS:85167528857
SN - 2044-5385
VL - 13
JO - Blood cancer journal
JF - Blood cancer journal
IS - 1
M1 - 117
ER -